Methods to assess drug permeability across the blood-brain barrier.
about
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugsEffect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis studyABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood--brain barrier cell line, hCMEC/D3 [corrected]Permeability of endothelial and astrocyte cocultures: in vitro blood-brain barrier models for drug delivery studies.Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists.Brainpeps: the blood-brain barrier peptide database.Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studiesCerebral uptake of drugs in humans.Discovery of isoxazole analogues of sazetidine-A as selective α4β2-nicotinic acetylcholine receptor partial agonists for the treatment of depressionVitamin D prevents hypoxia/reoxygenation-induced blood-brain barrier disruption via vitamin D receptor-mediated NF-kB signaling pathways.A Genetic Algorithm Based Support Vector Machine Model for Blood-Brain Barrier Penetration Prediction.Analytical and biological methods for probing the blood-brain barrier.Drug interactions at the blood-brain barrier: fact or fantasy?Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue.Mitigating permeability-mediated risks in drug discovery.Development of a physiologically-based pharmacokinetic model of the rat central nervous system.Experimental methods and transport models for drug delivery across the blood-brain barrier.In vivo methods to study uptake of nanoparticles into the brain.Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.Efflux transporters in the blood-brain interfaces--in vitro and in vivo methods and correlations.Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB).Altered brain uptake of therapeutics in a triple transgenic mouse model of Alzheimer's disease.Identification of two immortalized cell lines, ECV304 and bEnd3, for in vitro permeability studies of blood-brain barrier.An electrodiffusion model for the blood-brain barrier permeability to charged molecules.Engineering the human blood-brain barrier in vitro.Time-course investigation of blood-brain barrier permeability and tight junction protein changes in a rat model of permanent focal ischemia.Computational prediction of CNS drug exposure based on a novel in vivo dataset.
P2860
Q21245491-26A606F5-056C-46B5-8E54-8C197958B92AQ33642314-14D63622-A89A-4F2D-BBE3-F835287F0646Q34036791-A531E36E-6D0B-4A42-BACE-065ED770DD9DQ34147665-33E7344C-EB58-4C34-B076-37D8B5ED9468Q34215376-BA1DDF70-6CDF-4AE8-981B-3DD8180EE68BQ34243408-189926B9-8643-4C0C-BD0E-21A7269536A4Q34250155-DB9812B5-6D38-450E-A4A0-D9BD48C60A97Q34643571-CF8E5BF5-8FF1-4235-83D5-A732D2405D70Q35402036-E6D4C01A-4D7C-4744-9EA6-B178486DF254Q35588458-7795C5F2-6771-4356-979A-32B1702E7D41Q36172940-489CE891-7D5C-4B2E-8B25-7F179B5E4E95Q37096694-F08D9F1B-243D-439F-87AC-966F95981B88Q37362486-CC81DFBD-9B56-44EB-AE59-61EC68E91E11Q37376245-E1B621E8-FDA7-4838-A61C-CD591D12A223Q37671826-BFD53E80-41CD-4A7F-959F-7391822BBF35Q37689854-D33BF732-C3B1-4AE3-AEA4-11DE0ADE821DQ37698934-74CEDEBB-BB47-48F8-9531-E2440583AE60Q37798178-0C35EFBC-5432-41D4-ADAB-0E7FB12FE531Q37942267-82829182-B65E-47AF-A561-0C8BB12F4DA9Q37991010-12C8BA6B-EDC0-4626-9387-35FC085CFD58Q38117056-833EF90E-96BD-47A2-B5B8-D97D00B57CB9Q38267318-149DAC61-FBEA-4469-8024-974F9C29BC03Q38570611-33AD2058-743D-4494-944E-D3883D4F129DQ39378837-3562B83A-CF53-435D-8E51-A419BB3EEF0AQ43707054-B2E90983-EE48-4656-A655-D1C55D2A5AA8Q43818035-FE0CE63D-74BC-4045-9208-FD938571D332Q45830811-BE1BE1D0-1E95-4AD6-A959-1C76EBD6E227Q47163222-E8C6504F-138D-42E1-97DE-AD3E12DDC1B0Q48361620-1053C9D4-D3FD-4620-AF62-465AF383297FQ48457163-32AFB44F-F89C-4677-A7BA-E1FD0EF27691
P2860
Methods to assess drug permeability across the blood-brain barrier.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Methods to assess drug permeability across the blood-brain barrier.
@ast
Methods to assess drug permeability across the blood-brain barrier.
@en
type
label
Methods to assess drug permeability across the blood-brain barrier.
@ast
Methods to assess drug permeability across the blood-brain barrier.
@en
prefLabel
Methods to assess drug permeability across the blood-brain barrier.
@ast
Methods to assess drug permeability across the blood-brain barrier.
@en
P2093
P2860
P356
P1476
Methods to assess drug permeability across the blood-brain barrier.
@en
P2093
Joseph A Nicolazzo
Susan A Charman
William N Charman
P2860
P304
P356
10.1211/JPP.58.3.0001
P577
2006-03-01T00:00:00Z